[go: up one dir, main page]

AR074760A1 - Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. - Google Patents

Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Info

Publication number
AR074760A1
AR074760A1 ARP090104925A ARP090104925A AR074760A1 AR 074760 A1 AR074760 A1 AR 074760A1 AR P090104925 A ARP090104925 A AR P090104925A AR P090104925 A ARP090104925 A AR P090104925A AR 074760 A1 AR074760 A1 AR 074760A1
Authority
AR
Argentina
Prior art keywords
substituted
group
cycloalkyl
alkyl
independently selected
Prior art date
Application number
ARP090104925A
Other languages
English (en)
Inventor
Jingyuan Ma
Jiangao Song
Aaron Novack
Xin Chen
Christopher J Rabbat
Phuongly Pham
Dong Fang Shi
Imad Fayek Nashashibi
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074760(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of AR074760A1 publication Critical patent/AR074760A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Secondary Cells (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan agonistas GPR120. Estos compuestos son de utilidad para el tratamiento de enfermedades metabólicas, inclusive diabetes Tipo II y enfermedades asociadas con un control pobre de la glucemia. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) o una sal aceptable farmacéuticamente del mismo, donde: el grupo J se encuentra ausente o se selecciona entre el grupo que consiste en fórmulas (2); el anillo Q se selecciona entre el grupo que consiste en arilo, heteroarilo, grupo de fórmulas 3, donde Q se sustituye opcionalmente con (R6)k; A1, A2, A3 y A4 se seleccionan de manera independiente entre el grupo que consiste en N y C, con la condición de que sólo 0, 1 o 2 de A1, A2, A3 y A4 es N; T1, T2, T3 y T4 se seleccionan de manera independiente entre el grupo que consiste en N, O, CR1 y CR1R2, con la condición de que sólo 0, 1 o 2 de T1, T2, T3 y T4 se selecciona entre N y O; W1, W2, W3 y W4 se seleccionan de manera independiente entre el grupo que consiste en N, NRa, CR1, CR1R2, O, S, S(O) y S(O)2, con la condición de que el anillo J no es 1,3-dioxolano; E1, E2 y E3 se seleccionan de manera independiente entre el grupo que consiste en C y N; uno de X e Y es una unión, -CH2-, -CHD-, o -CD2-, y el otro de X e Y se selecciona entre el grupo que consiste en -CH2-, -CHD-, -CD2-, -C(O), -C(O)NRa, -NRa-, -O-, -S, -S(O)- y -S(O)2-; L es -(CR4R5)q- donde opcionalmente un -(CR4R5)- se reemplaza con -N-, -O-, -S-, -CR4=CR5-, o -fenil-; G se selecciona entre el grupo que consiste en -C(O)OZ y -C(O)NZ2; cada Z se selecciona de manera independiente entre el grupo que consiste en H, alquilo y alquilo sustituido; cada R1 y R2 se selecciona de manera independiente entre el grupo que consiste en H, deuterio, halo, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, oxo, alcoxi, alcoxi sustituido, CN, -NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, NRaC(O)Rb, -SRa, -S(O)Ra y -S(O)2Ra, y opcionalmente R1 y R2 se pueden ciclizar para formar un heterociclilo C3-7, heterociclilo C3-7 sustituido, espiro heterociclilo C3-7, espiro heterociclilo C3-7 sustituido, cicloalquilo C3-7, cicloalquilo C3-7 sustituido, espiro cicloalquilo C3-7 o espiro cicloalquilo C3-7 sustituido; cada R3 se selecciona de manera independiente entre el grupo que consiste en H, halo, alquilo, alquilo sustituido, alcoxi, alcoxi sustituido, -C(O)NRaRb, -NRaC(O)Rb, -NRaRb, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, ariloxi, ariloxi sustituido y -CN; cada R4 y R5 se selecciona de manera independiente entre el grupo que consiste en H, deuterio, flúor, alquilo, alquilo sustituido, alcoxi y alcoxi sustituido, y opcionalmente R4 y R5 se pueden ciclizar para formar un heterociclilo C3-7, heterociclilo C3-7 sustituido, espiro heterociclilo C3-7, espiro heterociclilo C3-7 sustituido, cicloalquilo C3-7, cicloalquilo C3-7 sustituido, espiro cicloalquilo C3-7 o espiro cicloalquilo C3-7sustituido; cada R6 se selecciona de manera independiente entre el grupo que consiste en H, halo, alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, CN, -ORa, -NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -NRaC(O)Rb, -SRa, -S(O)Ra y S(O)2Ra; cada uno de Ra y Rb se selecciona de manera independiente entre el grupo que consiste en H, alquilo, alquilo sustituido, cicloalquilo, heterociclilo, heterociclo sustituido, alquenilo, alquinilo, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, el subíndice k es 0, 1, 2 o 3; el subíndice m es 0, 1, 2 o 3; y el subíndice q es 0, 1, 2, 3 o 4.
ARP090104925A 2008-12-18 2009-12-16 Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. AR074760A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13892308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
AR074760A1 true AR074760A1 (es) 2011-02-09

Family

ID=41818563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104925A AR074760A1 (es) 2008-12-18 2009-12-16 Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Country Status (27)

Country Link
US (3) US8309600B2 (es)
EP (2) EP2367793B8 (es)
JP (1) JP5746975B2 (es)
KR (1) KR20110096071A (es)
CN (2) CN102307860B (es)
AR (1) AR074760A1 (es)
AU (1) AU2009335797A1 (es)
BR (1) BRPI0922483A2 (es)
CA (1) CA2746762A1 (es)
CL (1) CL2011001497A1 (es)
CO (1) CO6400136A2 (es)
CR (1) CR20110344A (es)
DK (1) DK2367793T3 (es)
EA (1) EA021515B1 (es)
EC (1) ECSP11011149A (es)
ES (1) ES2416980T3 (es)
HK (1) HK1162023A1 (es)
IL (1) IL213569A0 (es)
MX (1) MX2011006574A (es)
NI (1) NI201100126A (es)
NZ (2) NZ611429A (es)
SG (2) SG196838A1 (es)
SV (1) SV2011003954A (es)
TW (1) TW201028389A (es)
UA (1) UA105779C2 (es)
WO (1) WO2010080537A1 (es)
ZA (1) ZA201104570B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019001B1 (ru) * 2008-06-24 2013-12-30 Айрм Ллк Соединения и способы модулирования рецепторов, связанных с белком g
AU2009307656B2 (en) * 2008-10-21 2015-07-02 Cymabay Therapeutics, Inc. Aryl GPR120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
DK2582674T3 (en) * 2010-06-16 2014-12-15 Cymabay Therapeutics Inc GPR120 receptor agonists and uses thereof.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN103080769A (zh) 2010-09-14 2013-05-01 松下电器产业株式会社 雷达装置
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso
WO2013104257A1 (zh) * 2012-01-12 2013-07-18 江苏恒瑞医药股份有限公司 多环类衍生物、其制备方法及其在医药上的应用
US10130326B2 (en) 2012-01-20 2018-11-20 Ananth Annapragada Methods and compositions for objectively characterizing medical images
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9708270B2 (en) 2012-10-11 2017-07-18 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as GPR120 agonists
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
EP2970157B1 (en) * 2013-03-14 2018-04-25 Janssen Pharmaceutica NV Benzo-fused heterocyclic derivatives useful as agonists of gpr120
ES2690145T3 (es) 2013-03-14 2018-11-19 Janssen Pharmaceutica Nv Agonistas de GPR120 para el tratamiento de diabetes de tipo 2
CN105008345A (zh) 2013-03-14 2015-10-28 詹森药业有限公司 可用作gpr120的激动剂的双环吡咯衍生物
CN104109115B (zh) * 2013-04-16 2016-11-23 中国科学院上海药物研究所 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
CA2912747C (en) 2013-06-27 2021-05-04 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
CA2935897C (en) 2014-02-19 2018-07-03 Piramal Enterprises Limited Compounds for use as gpr120 agonists
CA2941445A1 (en) * 2014-03-07 2015-09-11 Janssen Pharmaceutica Nv Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
US9944649B2 (en) 2014-05-01 2018-04-17 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CU24401B1 (es) 2014-05-01 2019-05-03 Novartis Ag Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7)
CA2955919A1 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
CA2960757C (en) 2014-09-11 2022-09-06 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
ES2743704T3 (es) 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
CA2974060C (en) 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107176944B (zh) * 2016-03-11 2020-05-01 中国科学院上海药物研究所 一种噻吩羧酸类化合物或其衍生物、其药物组合物、制备方法和用途
KR20190017030A (ko) 2016-06-13 2019-02-19 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Dnmt1의 억제제로서의 치환된 피리딘
KR102539877B1 (ko) 2016-09-12 2023-06-05 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 이환형 화합물
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
CN116178473A (zh) * 2018-12-10 2023-05-30 江西青峰药业有限公司 一种奥贝胆酸的制备方法
CN109694332A (zh) * 2018-12-27 2019-04-30 四川大学 一种苄胺衍生物烯基化的方法
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US20240109865A1 (en) 2020-12-30 2024-04-04 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2022182954A1 (en) * 2021-02-26 2022-09-01 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating type 2 diabetes using granulocyte-macrophage colony-stimulating factor (gm-csf)
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
EP4493558A1 (en) 2022-03-17 2025-01-22 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1437781A (en) * 1972-04-04 1976-06-03 Beecham Group Ltd Pyridine derivatives having hypoglycaemic activity
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
US4705554A (en) * 1985-12-03 1987-11-10 Mitsubishi Chemical Industries Limited Benzofuranyloxyphenylurea derivative and herbicidal composition containing it as an active ingredient
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
EP0291245B1 (en) * 1987-05-11 1992-07-22 Ono Pharmaceutical Co., Ltd. Benzoylaminophenoxybutanoic acid derivatives
US4959092A (en) * 1987-06-03 1990-09-25 Mitsubishi Kasei Corporation Substituted phenyl (or pyridyl) urea compound and herbicidal composition containing the same as active ingredient
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
CA2238376C (en) * 1995-12-05 2006-08-15 Darwin Discovery Limited Benzofuran carboxamides and sulphonamides
DK0923568T5 (da) 1996-08-19 2003-11-03 Altana Pharma Ag Hidtil ukendte benzofuran-4-carboxamider
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003254781A1 (en) 2002-07-31 2004-02-16 Nippon Soda Co., Ltd. Aminosalicylamide derivative, process for producing the same and agri-horticultural pesticide
TWI343915B (en) 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CN1735408A (zh) * 2002-11-08 2006-02-15 武田药品工业株式会社 受体机能调节剂
AU2003296405A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1688138A4 (en) * 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
EP1706386A1 (en) * 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
WO2005080340A1 (en) 2004-02-18 2005-09-01 Metabolex, Inc. Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
CN1946666A (zh) 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
WO2006057448A1 (ja) 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
ES2378776T3 (es) * 2004-12-13 2012-04-17 Ono Pharmaceutical Co., Ltd. Derivado de ácido aminocarboxílico y uso medicinal del mismo
US8288438B2 (en) 2005-03-21 2012-10-16 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
WO2007008963A1 (en) * 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2007106469A2 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
RS53230B (en) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited CONDENSED CYCLICAL UNITS AS GPR40 RECEPTOR MODULATORS
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008054674A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
AU2008218951B2 (en) 2007-02-22 2011-11-17 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
JP5674463B2 (ja) 2007-06-05 2015-02-25 サノフイ 置換されたベンゾイルアミノ−インダン−２−カルボン酸及び関連化合物
WO2009046371A1 (en) 2007-10-05 2009-04-09 Metabolex, Inc. Methods of treating metabolic diseases
BRPI0818253A2 (pt) 2007-10-10 2015-04-07 Amgen Inc Moduladores de gpr40 bifenil substituídos
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びｐｐａｒ活性化剤
WO2009147990A1 (ja) 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
AU2009307656B2 (en) * 2008-10-21 2015-07-02 Cymabay Therapeutics, Inc. Aryl GPR120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Also Published As

Publication number Publication date
WO2010080537A1 (en) 2010-07-15
DK2367793T3 (da) 2013-07-01
EP2367793B8 (en) 2014-03-05
TW201028389A (en) 2010-08-01
EP2367793A1 (en) 2011-09-28
EA021515B1 (ru) 2015-07-30
ZA201104570B (en) 2012-09-26
HK1162023A1 (en) 2012-08-17
CO6400136A2 (es) 2012-03-15
SV2011003954A (es) 2011-12-06
AU2009335797A1 (en) 2011-07-14
NI201100126A (es) 2012-03-15
JP5746975B2 (ja) 2015-07-08
NZ611429A (en) 2014-12-24
CN102307860B (zh) 2014-07-02
UA105779C2 (uk) 2014-06-25
EP2367793B1 (en) 2013-03-27
US8309600B2 (en) 2012-11-13
SG196838A1 (en) 2014-02-13
CN102307860A (zh) 2012-01-04
US20140121246A1 (en) 2014-05-01
BRPI0922483A2 (pt) 2015-12-15
US20130131351A1 (en) 2013-05-23
US20100190831A1 (en) 2010-07-29
SG172125A1 (en) 2011-07-28
EA201190053A1 (ru) 2012-02-28
CA2746762A1 (en) 2010-07-15
US8598374B2 (en) 2013-12-03
CR20110344A (es) 2011-09-22
ECSP11011149A (es) 2011-08-31
JP2012512893A (ja) 2012-06-07
EP2514745A1 (en) 2012-10-24
ES2416980T3 (es) 2013-08-05
CN103980235A (zh) 2014-08-13
IL213569A0 (en) 2011-07-31
CL2011001497A1 (es) 2011-09-30
KR20110096071A (ko) 2011-08-26
NZ593906A (en) 2013-07-26
MX2011006574A (es) 2011-08-03

Similar Documents

Publication Publication Date Title
AR074760A1 (es) Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
PE20091222A1 (es) Bifenilo sustituidos como moduladores del receptor gpra40
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR076836A1 (es) Inhibidores del canal de potasio medular externo renal
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
CO6210770A2 (es) Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20130155A1 (es) Derivados de ariletinilo
PE20120656A1 (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR064459A1 (es) Derivados de sulfonamida
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
AR075510A1 (es) Inhibidores del virus de la hepatitis c
PE20160217A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
PE20171155A1 (es) Metodos y compuestos para tratar infecciones virales por paramyxoviridae
AR059512A1 (es) Derivados de piridina -2- carboxamida
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR061644A1 (es) Derivados de benzofurano
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
PE20181492A1 (es) Compuestos sustituidos de 4-fenilpiridina como agonistas de tgr5 no sistemicos
PE20091381A1 (es) Inhibidores del virus de la hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure